Patents Assigned to NeoRx Corporation
-
Patent number: 7115248Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: GrantFiled: April 8, 2004Date of Patent: October 3, 2006Assignee: NeoRx CorporationInventors: Sudhakar Kasina, John M Reno, Louis J Theodore
-
Patent number: 7115720Abstract: The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a radionuclide. The complexes are useful as diagnostic agents and as therapeutic agents. The invention also provides methods and intermediates useful for preparing the complexes of the invention, as well as therapeutic and diagnostic methods.Type: GrantFiled: July 8, 2003Date of Patent: October 3, 2006Assignee: Neorx CorporationInventor: Alan R. Fritzberg
-
Patent number: 7097823Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: February 23, 2004Date of Patent: August 29, 2006Assignee: NEORX CorporationInventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
-
Patent number: 7094885Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: June 20, 2003Date of Patent: August 22, 2006Assignee: NeoRx CorporationInventor: Alan R. Fritzberg
-
Patent number: 7094550Abstract: A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C?O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro.Type: GrantFiled: March 26, 2002Date of Patent: August 22, 2006Assignee: NeoRx CorporationInventors: David J. Grainger, Paul R. Kemp
-
Patent number: 7084171Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.Type: GrantFiled: April 19, 2004Date of Patent: August 1, 2006Assignee: NeoRx CorporationInventors: David J. Grainger, James C. Metcalfe, Sudhakar Kasina
-
Patent number: 7070759Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: January 24, 2005Date of Patent: July 4, 2006Assignee: NeoRx CorporationInventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
-
Patent number: 6936700Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: GrantFiled: January 17, 2003Date of Patent: August 30, 2005Assignee: NeoRx CorporationInventor: Sudhakar Kasina
-
Publication number: 20050100545Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.Type: ApplicationFiled: July 31, 2003Publication date: May 12, 2005Applicant: NeoRx CorporationInventors: Scott Graves, John Reno, Robert Mallett, Mark Hylarides
-
Publication number: 20050036948Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: ApplicationFiled: April 8, 2004Publication date: February 17, 2005Applicant: NeoRx CorporationInventors: Sudhakar Kasina, John Reno, Louis Theodore
-
Publication number: 20050008635Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.Type: ApplicationFiled: February 25, 2004Publication date: January 13, 2005Applicant: NeoRx CorporationInventors: Scott Graves, John Reno, Robert Mallett, Mark Hylarides, Stephen Searle, Andrew Henry, Jan Pedersen, Anthony Rees
-
Publication number: 20040241172Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: ApplicationFiled: February 10, 2004Publication date: December 2, 2004Applicant: NeoRx CorporationInventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Alan R. Fritzberg
-
Patent number: 6767531Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: December 11, 2001Date of Patent: July 27, 2004Assignee: NeoRx CorporationInventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
-
Patent number: 6734208Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.Type: GrantFiled: June 13, 2002Date of Patent: May 11, 2004Assignee: NeoRx CorporationInventors: David J. Grainger, James C. Metcalfe, Sudhakar Kasina
-
Patent number: 6709652Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.Type: GrantFiled: August 1, 2001Date of Patent: March 23, 2004Assignee: NeoRx CorporationInventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
-
Patent number: 6663881Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: GrantFiled: December 18, 2001Date of Patent: December 16, 2003Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, John M. Reno
-
Publication number: 20030220233Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: ApplicationFiled: June 6, 2003Publication date: November 27, 2003Applicant: NeoRx CorporationInventors: Sudhakar Kasina, John M. Reno, Louis J. Theodore
-
Publication number: 20030203958Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: ApplicationFiled: December 27, 2002Publication date: October 30, 2003Applicant: NeoRx CorporationInventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
-
Publication number: 20030158393Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: ApplicationFiled: January 17, 2003Publication date: August 21, 2003Applicant: NeoRx CorporationInventor: Sudhakar Kasina
-
Publication number: 20030143233Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, in the absence and presence of a radiation-sensitizing agent, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.Type: ApplicationFiled: September 16, 2002Publication date: July 31, 2003Applicant: NeoRx CorporationInventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno, Erica A. Dearstyne